Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma who have previously received 1 to 3 lines of therapy.
Amgen’s Carfilzomib Approved for Multiple Myeloma
Carfilzomib, a proteasome inhibitor, has been approved by the FDA for use in combination with dexamethasone or lenalidomide, in patients with relapsed/refractory multiple myeloma (RRMM) who have previously received 1 to 3 lines of therapy.1 Also, the drug’s accelerated approval as a single agent has now been converted to a full approval—carfilzomib can be used alone in previously treated patients with RRMM.
The approval is based on phase 3 results of the ENDEAVOR study that were presented at the annual meeting of the American Society of Hematology2 and simultaneously published in Lancet Oncology. The randomized phase 3 study evaluated 929 adult patients with refractory multiple myeloma (RMM) who had received 1 to 3 prior lines of therapy. The study demonstrated that the doublet of carfilzomib and dexamethasone (Kd) significantly improved progressionfree survival (PFS) compared with bortezomib and dexamethasone (Vd) (median PFS, 18.7 vs 9.4 months; HR, 0.53; 95% CI, 0.44—0.65; P <.0001) in relapsed multiple myeloma. Bortezomib and dexamethasone are the current standard of care in multiple myeloma.
Grade 3 and greater adverse events (AEs) were significantly higher with Kd compared with Vd: 69.8% and 63.9%, respectively, in patients with 1 prior treatment, and 76.6% and 69.9%, respectively, in patients with at least 2 prior treatments. Grade 3 or higher hypertension, dyspnea, and cardiac failure were more common in the Kd group.
Now that the treatment is approved, cost will be the next big question for payers to develop coverage policies for the combination. Carfilzomib alone is estimated to cost $10,000 for a 28-day cycle in an average-sized patient.3 A recent health economic analysis of combination treatments commonly used in multiple myeloma by researchers at Novartis compared bortezomib plus dexamethasone; panobinostat, bortezomib, and dexamethasone; lenalidomide plus dexamethasone; lenalidomide, bortezomib, and dexamethasone; carfilzomib; carfilzomib, lenalidomide, and dexamethasone; and pomalidomide plus dexamethasone.4 The study examined the expenditures for drugs and their administration, for prophylaxis and adverse event monitoring, and for the treatment of grade 3 or 4 AEs.
carfilzomib
EBO
The authors concluded that the combination of , lenalidomide, and dexamethasone was the most expensive, because regimens that included lenalidomide were the most expensive (range was $126,000 to $256,000). The combination of bortezomib with dexamethasone and the combination of panobinostat, bortezomib, and dexamethasone, cost the least (less than $125,000). Quite importantly, the authors found that combining carfilzomib, lenalidomide, and dexamethasone incurred the highest medical costs. Since one of the regimens that has now been approved by the FDA is carfilzomib and dexamethasone, the safety and cost-effectiveness of this combination in the real world remains to be seen.
References
1. FDA approves new Kyprolis (carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma [press release]. Thousand Oaks, CA: Amgen; January 21, 2016. http://www.amgen.com/media/ news-releases/2016/01/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patientswith- relapsed-or-refractory-multiple-myeloma/.
2. Page MR, and Dangi-Garimella S. Novel combinations in multiple myeloma and lymphoma. The American Journal of Managed Care website. http://www.ajmc.com/conferences/ash15/-novel-combinations-in-multiple-myeloma-andlymphoma/ p-1. Published December 8, 2015. Accessed January 22, 2016.
3. Myeloma Beacon Staff. FDA approves Kyprolis (carfilzomib) for relapsed and refractory multiple myeloma. The Myeloma Beacon website. http://www.myelomabeacon.com/news/2012/07/20/fda-approves-kyprolis-carfilzomibfor- relapsed-and-refractory-multiple-myeloma/. Published July 20, 2012. Accessed January 22, 2016.
4. Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204-215.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More